Breda, the Netherlands- arGEN-X N.V. (Euronext Brussels: ARGX, hereinafter: the "Company"), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announces that an annual general meeting of shareholders will be held on Wednesday 13 May 2015.
The shareholders and all other persons with meeting rights to attend the annual general meeting of shareholders of the Company are invited to attend the annual general meeting of shareholders, to be held at 9:00 AM on Wednesday 13 May 2015 at Hilton Amsterdam Schiphol Airport, Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.
AGENDA
Next to recurrent items on the agenda such as the adoption of the 2014 Annual Accounts and the authorisation of the board of directors to limit or exclude pre-emptive rights, the following is, amongst other, proposed:
- approval of the arGEN-X Option Plan, originally adopted by the board of directors on 13 November 2009 and as lastly amended on 18 December 2014 (agenda item 3a)
- appointment of Mr. J. D. deBethizy, PhD as a non-executive member of the board of directors (agenda item 7); and
- appointment of Deloitte Accountants B.V. as the Company's accountant for the 2015 financial year (agenda item 11).
RELEVANT DOCUMENTATION
Here you can find thenotice of convocation, including information for shareholders regarding the attendance of the meeting and notification and registration for the meeting, theagendaand theexplanatory notes. The 2014 Annual Report and the proposal for the arGEN-X Option Plan may be viewed and downloaded viawww.argenx.comand will be available for examination at the offices of arGEN-X, Technologiepark 30, 9052 Zwijnaarde, Belgium. Copies of these documents may be obtained free of charge at this address.
